|
|
Type of Company:
Type:
|
Company
|
Ownership: |
Publicly Traded (ABCL, NASDAQ) |
Company Size: |
100-499 Employees In BC (100-499 Total)
100-499 In BC (100-499 Total)
|
Year Founded: |
2012 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
AbCellera, drug discovery platform, antibodies, genomics, antibody therapeutics
|
Profile Views: |
7,924 Company Profile Views |
|
|
|
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Its full-stack, AI-powered drug discovery platform integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science.
We partner with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development |
|
|
Date |
Type |
Amount |
Investors |
May 4, 2020 |
Unattributed |
$175.6 Million CAD |
Government of Canada under Innovation, Science and Economic Development's (ISED) Strategic Innovation Fund (SIF) |
May 27, 2020 |
Series B |
$105 Million USD |
The financing was led by OrbiMed and current investor DCVC Bio, with an investor syndicate that includes Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Company, University of Minnesota, and Presight Capital. |
Dec 11, 2020 |
IPO |
$483 Million USD |
Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets are acting as joint book-running managers for the offering. |
Date |
Type |
Amount |
Investors |
May 4, 2020 |
Unattributed |
$175.6M CAD |
Government of Canada under Innovation, Science and Economic Development's (ISED) Strategic Innovation Fund (SIF) |
May 27, 2020 |
Series B |
$105M USD |
The financing was led by OrbiMed and current investor DCVC Bio, with an investor syndicate that includes Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Company, University of Minnesota, and Presight Capital. |
Dec 11, 2020 |
IPO |
$483M USD |
Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets are acting as joint book-running managers for the offering. |
|
|
|
|
|
May 13, 2022
|
AbCellera Reports Q1 2022 Business Results, Q1 Revenue up Sharply YoY to US $317 Million
|
|
May 5, 2022
|
AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration
|
|
Apr 19, 2022
|
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
|
|
Mar 1, 2022
|
AbCellera Reports Full Year 2021 Business Results, Total Revenue of US $375 Million (Up From $233M in 2020), and Liquidity of Over $720M
|
|
Feb 14, 2022
|
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
|
|
Feb 11, 2022
|
Eli Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab (Worth $720 Million), to the U.S. Government
|
|
Dec 16, 2021
|
AbCellera Announces Changes to Its Board of Directors
|
|
Dec 8, 2021
|
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer
|
|
Dec 6, 2021
|
AbCellera-Discovered Bamlanivimab Authorized for Emergency Use in COVID-19 Patients Under the Age of 12
|
|
Nov 22, 2021
|
AbCellera Reports Q3 2021 Business Results
|
|
|
1 - 10 of 78 results
|
|
 |
|
|
|
Share This Company Profile |
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
